Use of clofarabine for acute childhood leukemia.

about

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.

P2860

Q36987975-89AE18E1-89BE-4E82-BB86-8CE347A2FE5B Q37649646-905B791C-C816-4BF8-ABB4-08AB546A0CD1

P2860

Use of clofarabine for acute childhood leukemia.

Item

http://www.wikidata.org/entity/Q42737704

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Use of clofarabine for acute childhood leukemia.

@en

Use of clofarabine for acute childhood leukemia.

@nl

type

Item

label

Use of clofarabine for acute childhood leukemia.

@en

Use of clofarabine for acute childhood leukemia.

@nl

prefLabel

Use of clofarabine for acute childhood leukemia.

@en

Use of clofarabine for acute childhood leukemia.

@nl

P1476

Use of clofarabine for acute childhood leukemia

@en

P2093

A Martoni

http://www.w3.org/2001/XMLSchema#string

A Pession

http://www.w3.org/2001/XMLSchema#string

K Kleinschmidt

http://www.w3.org/2001/XMLSchema#string

R Masetti

http://www.w3.org/2001/XMLSchema#string

P2860

Fifty years of studies of the biology and therapy of childhood leukemia

Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate

Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Clofarabine: past, present, and future.

Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.

Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine.

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal

P304

111-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S10123

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20631817

http://www.w3.org/2001/XMLSchema#string

P932

2898101

http://www.w3.org/2001/XMLSchema#string

Use of clofarabine for acute childhood leukemia.

about

P2860

P2860

Use of clofarabine for acute childhood leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932